Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

REMEVi vs TeleCareSpot

REMEVi
Graded #70

Higher grade

vs+5.799999999999997
TeleCareSpot
Graded #160

Lower grade

The verdict

REMEVi takes it — 73.5/100 to 67.7/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +14
57
43
Dose & formulationEven
83
83
Clinical oversightREMEVi +3
86
83
Labs & monitoringREMEVi +3
55
52
FulfillmentREMEVi +5
97
92
Contract termsREMEVi +8
69
61
REMEVi · left barTeleCareSpot · right bar

The numbers

MetricREMEViTeleCareSpot
WeighScore73.5/10067.7/100
GradeCC
Scorecard rank#70#160
Semaglutide$219/mo$299/mo (all doses, plus a separate fee, compounded)
Tirzepatide$319/mo$399/mo
CoverageAll 50 states48 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
TeleCareSpot

Graded #160 · C

Strengths

  • Flat, all-inclusive monthly pricing with no hidden fees — compounded semaglutide $299/month and tirzepatide $399/month, all doses included
  • Verifiable LegitScript certification (seal ID 45936855) plus HIPAA compliance and licensed US physicians
  • Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
  • DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
  • Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Not available in Alaska, Mississippi, or New Jersey
  • The compounding pharmacy partner is not named
  • A separate weight-loss consultation fee applies (credited toward your medication package if approved)
  • Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard